Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.

Thymic stromal lymphopoietin (TSLP) is a cytokine released by human lung epithelium in response to external insult. Considered as a master switch in T helper 2 lymphocyte (Th2) mediated responses, TSLP is believed to play a key role in allergic diseases including asthma. The aim of this study was to...

Full description

Bibliographic Details
Main Authors: Adelina Orellana, Vicente García-González, Rosa López, Sonia Pascual-Guiral, Estrella Lozoya, Julia Díaz, Daniel Casals, Antolín Barrena, Stephane Paris, Miriam Andrés, Victor Segarra, Dolors Vilella, Rajneesh Malhotra, Paul Eastwood, Anna Planagumà, Montserrat Miralpeix, Arsenio Nueda
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2018-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5761851?pdf=render
id doaj-c80cf08071ce4fa99740c728ba8e54ad
record_format Article
spelling doaj-c80cf08071ce4fa99740c728ba8e54ad2020-11-25T01:52:50ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01131e018924710.1371/journal.pone.0189247Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.Adelina OrellanaVicente García-GonzálezRosa LópezSonia Pascual-GuiralEstrella LozoyaJulia DíazDaniel CasalsAntolín BarrenaStephane ParisMiriam AndrésVictor SegarraDolors VilellaRajneesh MalhotraPaul EastwoodAnna PlanagumàMontserrat MiralpeixArsenio NuedaThymic stromal lymphopoietin (TSLP) is a cytokine released by human lung epithelium in response to external insult. Considered as a master switch in T helper 2 lymphocyte (Th2) mediated responses, TSLP is believed to play a key role in allergic diseases including asthma. The aim of this study was to use a phenotypic approach to identify new biological and chemical starting points for inhibition of TSLP production in human bronchial epithelial cells (NHBE), with the objective of reducing Th2-mediated airway inflammation. To this end, a phenotypic screen was performed using poly I:C / IL-4 stimulated NHBE cells interrogated with a 44,974 compound library. As a result, 85 hits which downregulated TSLP protein and mRNA levels were identified and a representative subset of 7 hits was selected for further characterization. These molecules inhibited the activity of several members of the MAPK, PI3K and tyrosine kinase families and some of them have been reported as modulators of cellular phenotypic endpoints like cell-cell contacts, microtubule polymerization and caspase activation. Characterization of the biological profile of the hits suggested that mTOR could be a key activity involved in the regulation of TSLP production in NHBE cells. Among other targeted kinases, inhibition of p38 MAPK and JAK kinases showed different degrees of correlation with TSLP downregulation, while Syk kinase did not seem to be related. Overall, inhibition of TSLP production by the selected hits, rather than resulting from inhibition of single isolated targets, appeared to be due to a combination of activities with different levels of relevance. Finally, a hit expansion exercise yielded additional active compounds that could be amenable to further optimization, providing an opportunity to dissociate TSLP inhibition from other non-desired activities. This study illustrates the potential of phenotypic drug discovery to complement target based approaches by providing new chemistry and biology leads.http://europepmc.org/articles/PMC5761851?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Adelina Orellana
Vicente García-González
Rosa López
Sonia Pascual-Guiral
Estrella Lozoya
Julia Díaz
Daniel Casals
Antolín Barrena
Stephane Paris
Miriam Andrés
Victor Segarra
Dolors Vilella
Rajneesh Malhotra
Paul Eastwood
Anna Planagumà
Montserrat Miralpeix
Arsenio Nueda
spellingShingle Adelina Orellana
Vicente García-González
Rosa López
Sonia Pascual-Guiral
Estrella Lozoya
Julia Díaz
Daniel Casals
Antolín Barrena
Stephane Paris
Miriam Andrés
Victor Segarra
Dolors Vilella
Rajneesh Malhotra
Paul Eastwood
Anna Planagumà
Montserrat Miralpeix
Arsenio Nueda
Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.
PLoS ONE
author_facet Adelina Orellana
Vicente García-González
Rosa López
Sonia Pascual-Guiral
Estrella Lozoya
Julia Díaz
Daniel Casals
Antolín Barrena
Stephane Paris
Miriam Andrés
Victor Segarra
Dolors Vilella
Rajneesh Malhotra
Paul Eastwood
Anna Planagumà
Montserrat Miralpeix
Arsenio Nueda
author_sort Adelina Orellana
title Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.
title_short Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.
title_full Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.
title_fullStr Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.
title_full_unstemmed Application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of TSLP production in lung epithelial cells.
title_sort application of a phenotypic drug discovery strategy to identify biological and chemical starting points for inhibition of tslp production in lung epithelial cells.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2018-01-01
description Thymic stromal lymphopoietin (TSLP) is a cytokine released by human lung epithelium in response to external insult. Considered as a master switch in T helper 2 lymphocyte (Th2) mediated responses, TSLP is believed to play a key role in allergic diseases including asthma. The aim of this study was to use a phenotypic approach to identify new biological and chemical starting points for inhibition of TSLP production in human bronchial epithelial cells (NHBE), with the objective of reducing Th2-mediated airway inflammation. To this end, a phenotypic screen was performed using poly I:C / IL-4 stimulated NHBE cells interrogated with a 44,974 compound library. As a result, 85 hits which downregulated TSLP protein and mRNA levels were identified and a representative subset of 7 hits was selected for further characterization. These molecules inhibited the activity of several members of the MAPK, PI3K and tyrosine kinase families and some of them have been reported as modulators of cellular phenotypic endpoints like cell-cell contacts, microtubule polymerization and caspase activation. Characterization of the biological profile of the hits suggested that mTOR could be a key activity involved in the regulation of TSLP production in NHBE cells. Among other targeted kinases, inhibition of p38 MAPK and JAK kinases showed different degrees of correlation with TSLP downregulation, while Syk kinase did not seem to be related. Overall, inhibition of TSLP production by the selected hits, rather than resulting from inhibition of single isolated targets, appeared to be due to a combination of activities with different levels of relevance. Finally, a hit expansion exercise yielded additional active compounds that could be amenable to further optimization, providing an opportunity to dissociate TSLP inhibition from other non-desired activities. This study illustrates the potential of phenotypic drug discovery to complement target based approaches by providing new chemistry and biology leads.
url http://europepmc.org/articles/PMC5761851?pdf=render
work_keys_str_mv AT adelinaorellana applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT vicentegarciagonzalez applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT rosalopez applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT soniapascualguiral applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT estrellalozoya applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT juliadiaz applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT danielcasals applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT antolinbarrena applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT stephaneparis applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT miriamandres applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT victorsegarra applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT dolorsvilella applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT rajneeshmalhotra applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT pauleastwood applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT annaplanaguma applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT montserratmiralpeix applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
AT arsenionueda applicationofaphenotypicdrugdiscoverystrategytoidentifybiologicalandchemicalstartingpointsforinhibitionoftslpproductioninlungepithelialcells
_version_ 1724992573913694208